Overall Survival Miss
Threshold's Stock Slammed on Pancreatic Cancer Drug Data
By Catherine Shaffer
Monday, September 17, 2012
Threshold Pharmaceuticals Inc. saw its shares fall 19.7 percent Monday, following release of an update to its Phase IIb trial of TH-302 in pancreatic cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.